GHK-Cu: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 15 sources cited

Overview

GHK-Cu (copper peptide, glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Discovered by Dr. Loren Pickart in the 1970s, GHK-Cu declines dramatically with age — from ~200 ng/mL at age 20 to ~80 ng/mL by age 60. It is one of the most gene-modulating peptides known, influencing the expression of over 4,000 human genes — approximately 31% of the genome — in cultured human cells, with a broad shift toward regenerative, anti-inflammatory, and tissue-remodeling activity. GHK-Cu is studied for wound healing, skin rejuvenation, hair growth, bone repair, and systemic anti-aging.

Mechanism of Action

GHK-Cu operates through an extraordinarily diverse array of molecular mechanisms, making it arguably the most pleiotropic peptide in therapeutic use. Its effects stem from three interconnected capabilities: copper delivery, direct signaling, and gene expression remodeling. As a copper chaperone, GHK-Cu delivers bioavailable copper(II) ions to tissue sites where copper-dependent enzymes are critical. Copper is an essential cofactor for lysyl oxidase (collagen and elastin crosslinking), superoxide dismutase (antioxidant defense), cytochrome c oxidase (mitochondrial energy production), and tyrosinase (melanin synthesis). By supplying copper precisely where it is needed, GHK-Cu activates these enzymes and supports their downstream biological functions — from structural tissue integrity to cellular energy metabolism. Beyond copper delivery, GHK-Cu directly modulates gene expression on a massive scale. A 2012 genomics study that searched the Broad Institute's Connectivity Map identified GHK as a compound able to reverse the gene-expression signature of emphysema-damaged lung tissue. It upregulates genes involved in collagen synthesis (COL1A1, COL3A1), extracellular matrix remodeling (TIMPs, decorin), stem cell markers (p63, integrin β1), antioxidant enzymes (SOD1, SOD3, glutathione-S-transferases), DNA repair (GADD45A, XPC), and ubiquitin-proteasome pathways (clearing damaged proteins). In cell and animal studies it also lowers inflammatory signalling (IL-6, TNF-α, NFκB pathway), and it modulates matrix metalloproteinases and their inhibitors rather than simply suppressing them: in fibroblast cultures it increased MMP-1, MMP-2, TIMP-1 and TIMP-2. This bidirectional gene modulation — simultaneously activating repair programs while suppressing destructive ones — is what makes GHK-Cu unique among therapeutic peptides. In wound healing, GHK-Cu accelerates all four phases: hemostasis (platelet aggregation), inflammation (macrophage recruitment followed by resolution), proliferation (fibroblast migration, angiogenesis, collagen deposition), and remodeling (scar-free tissue maturation). It attracts immune cells, mast cells, and endothelial cells to wound sites through chemotactic signaling. For skin aging, GHK-Cu stimulates dermal fibroblasts to produce collagen I, III, and V, increases elastin synthesis, rebuilds the glycosaminoglycan ground substance (hyaluronic acid, dermatan sulfate), and improves dermal vascularity. It also promotes hair growth by increasing follicular proliferation and enlarging hair follicle size — likely through Wnt/β-catenin pathway activation. In cell and animal studies, GHK-Cu has demonstrated neuroprotective effects (upregulating brain antioxidant genes), anti-anxiety activity, bone remodeling (osteoblast stimulation, osteoclast inhibition), and anti-cancer gene expression signatures in genomic studies.

GHK-Cu Benefits: What the Research Shows

  • Dr. Loren Pickart's original research in the 1970s–80s demonstrated that GHK-Cu in human plasma was responsible for the ability of young blood to stimulate old liver tissue to synthesize proteins at a youthful rate (Biochemical and Biophysical Research Communications, 1973)
  • Analyses of the Broad Institute's Connectivity Map data by Pickart and colleagues (2014–2018) found GHK changed the expression of 31.2% of human genes by 50% or more in cultured cells, a pattern the authors describe as a shift toward healthier gene expression
  • Small cosmetic studies summarized in Pickart's reviews: GHK-Cu cream applied to thigh skin improved collagen production in 70% of the women treated (versus 50% with vitamin C cream and 40% with retinoic acid), and a 12-week facial cream study in 71 women with photoaged skin reported increased skin density and thickness. These were reported in a pilot study and conference presentations, not full peer-reviewed trials
  • In rat wound chambers, GHK-Cu increased collagen, total protein and glycosaminoglycan accumulation in a concentration-dependent manner (Journal of Clinical Investigation, 1993). In human trials of topical GHK-Cu, a gel improved closure of diabetic foot ulcers (98.5% vs 60.8% median area closure), but a 0.4% cream did no better than placebo for venous ulcers
  • A genomic analysis in Clinical & Experimental Metastasis (2010) defined a 54-gene signature of metastasis-prone colorectal cancer and, by querying the Connectivity Map, predicted that GHK could reverse the expression of these genes. This is a computational finding, not a test of GHK in cancer patients
  • Hair follicle organ culture: a closely related tripeptide-copper complex (AHK-Cu) stimulated elongation of human hair follicles ex vivo and proliferation of dermal papilla cells
  • In rats, collagen tubes carrying GHK placed around cut sciatic nerves raised nerve growth factor and neurotrophin levels in the regenerating tissue
  • In rat wounds and dermal fibroblast cultures, GHK-Cu increased decorin expression — decorin is a key proteoglycan that regulates collagen fibril assembly and has anti-fibrotic properties
  • Research on bone healing in guinea pigs showed that a collagen gel supplemented with GHK healed femoral bone defects faster than the same gel without GHK

GHK-Cu Dosage

  • Subcutaneous injection for systemic effects: 1–3 mg daily or every other day, cycled 4–8 weeks on, 2–4 weeks off
  • Topical application for skin/hair: 0.1–1% GHK-Cu cream or serum applied once or twice daily to target areas
  • Mesotherapy/microneedling protocol: 50–100 mcg per cm² delivered via microneedling to facial skin every 2–4 weeks
  • Hair loss protocol: 1–2 mg subcutaneous injection into scalp weekly, combined with daily topical application
  • Wound healing: 1–2 mg injected locally around wound margins daily for 5–10 days
  • Systemic anti-aging protocol: 2 mg subcutaneous injection daily for 30 days, repeated 2–3 times per year
  • Post-procedure recovery (laser, chemical peel): 1 mg subcutaneous daily for 7–14 days starting day of procedure
  • Injectable solution: reconstitute in bacteriostatic water; topical: compound in a suitable vehicle (hyaluronic acid base preferred)
GHK-Cu dosage calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

GHK-Cu Side Effects & Safety

Known Side Effects

  • Injection site reactions: transient redness, mild stinging, and occasional bruising (very common, resolves within minutes to hours)
  • Mild skin flushing after subcutaneous injection due to local vasodilation and mast cell activation
  • Topical application may cause temporary skin warmth or tingling, especially on sensitive skin or immediately after microneedling
  • Rare: temporary increase in hair shedding during first 2 weeks of use (telogen effluvium-like, precedes new growth)
  • At high systemic doses (>5 mg/day), potential for copper accumulation — liver function monitoring advisable for long-term use
  • Nausea reported rarely with higher subcutaneous doses
  • Contact dermatitis possible with topical use in copper-sensitive individuals

Safety Profile

Topical GHK-Cu has decades of use in cosmetics and in wound-healing studies, with no safety issues reported in its discoverer's reviews, but injectable GHK-Cu has little human safety data. The FDA lists injectable GHK-Cu among bulk drug substances that may present significant safety risks in compounding, noting a possible risk of immunogenicity and that there are limited data in humans. Topical GHK-Cu has been used in commercial skincare products since the 1990s with an extensive post-market safety record. There are few human data on injectable GHK-Cu, so its adverse event profile is not established. The primary theoretical concern is copper overload with prolonged high-dose systemic use — copper is an essential trace element but is toxic in excess. Individuals with Wilson's disease (impaired copper metabolism) should absolutely avoid GHK-Cu. For healthy individuals, cycling is commonly used with the aim of limiting copper exposure, though this has not been studied. Liver function tests (including ceruloplasmin) are advisable for those using injectable GHK-Cu continuously beyond 8 weeks. No drug interaction studies have been done, and combinations with other peptides have not been studied. Pregnancy and breastfeeding: insufficient data, avoid as precaution.

What to Expect

This timeline is based on user reports and small cosmetic studies of topical GHK-Cu; there are few human data on injected GHK-Cu. Week 1–2: Skin may appear slightly flushed or have a subtle glow due to increased dermal vascularity. Injection sites heal quickly. If using topically, skin texture begins to feel smoother. Any initial hair shedding is possible as follicles reset to a synchronized growth phase. Weeks 3–4: Visible improvements in skin firmness and elasticity. Fine lines appear softer. Wound healing is noticeably accelerated. Hair may begin to appear thicker at the base if using for hair loss. Collagen synthesis is ramping up significantly. Weeks 5–8: Substantial improvements in skin quality — increased thickness, improved hydration, reduced hyperpigmentation. Joint comfort may improve as cartilage and connective tissue benefit. Hair growth becomes visible with new vellus hairs converting to terminal hairs in responsive individuals. Months 2–3: Peak benefits for a single course. Skin quality improvements are well-established and often commented on by others. Scars and stretch marks may appear lighter and smoother. Benefits persist for weeks to months after discontinuation due to the long-lasting nature of collagen and matrix remodeling.

Common Stacks

Storage & Handling

Store lyophilized GHK-Cu at 2–8°C for up to 12 months or -20°C for up to 24 months. GHK-Cu is a relatively stable tripeptide but the copper complex can be affected by pH extremes. Reconstitute with bacteriostatic water to desired concentration — typically 1–2 mL per vial. Once reconstituted, store at 2–8°C and use within 4–6 weeks. The reconstituted solution should have a faint blue tint (from the copper ion) — this is normal. If the solution turns green or forms precipitate, discard. For topical preparations, GHK-Cu is most stable at pH 5.5–6.5. Protect from prolonged light exposure.

Pricing & Available Variants

$53 – $65price range
50mg75mg100mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018.
  2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015.
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
  4. Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994.
  5. Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992.
  6. Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993.
  7. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988.
  8. Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012.
  9. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014.
  10. Hong Y, Downey T, Eu KW, et al. A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis. 2010.
  11. Siméon A, Wegrowski Y, Bontemps Y, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000.
  12. Siméon A, Emonard H, Hornebeck W, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000.
  13. Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007.
  14. Ahmed MR, Basha SH, Gopinath D, et al. Initial upregulation of growth factors and inflammatory mediators during nerve regeneration in the presence of cell adhesive peptide-incorporated collagen tubes. J Peripher Nerv Syst. 2005.
  15. Pohunková H, Stehlík J, Váchal J, et al. Morphological features of bone healing under the effect of collagen-graft-glycosaminoglycan copolymer supplemented with the tripeptide Gly-His-Lys. Biomaterials. 1996.

Related Peptides

Track GHK-Cu in Your Protocol

Log your GHK-Cu doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free